Comprehensive therapy
Comprehensive therapy has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Oct 11, 2026: “DYNAMICS OF MYOKINE STATUS AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SARCOPENIA RECEIVING COMPREHENSIVE THERAPY”.
1 paper studies it5 findingsUpdated
See all 1 papers on comprehensive therapy
At a glance
The findings reach people, from one lab or study. 1 lab.
“the reduction in insulin resistance was more pronounced in Group 1 (HOMA-IR decreased 1.74-fold versus 1.41-fold in Group 2)”
None of its findings points the other way.
- 1 lab
- Human trial1
Studies in people
1 study gave comprehensive therapy to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases HOMA-IR1.74-fold versus 1.41-fold down: Decreases myostatindecreased by 33.6% up: Increases irisin1.67-fold | Trialsix months | 35 people55 to 65 yearsMidlife adults; sarcopenia group (Group 1) compared with T2DM without sarcopenia | SOUTH ARAL SEA MEDICAL JOURNAL, Oct 11, 2026 |
What did studies of comprehensive therapy find?
5Studies of comprehensive therapy measured 5 outcomes, among them vitamin D, handgrip strength and irisin.
Vitamin D
upin humans1
1 study
Vitamin D
upin humans1
Comprehensive therapy increases vitamin D in humans (patients with sarcopenia).
“vitamin D reached optimal values”
Human trialpatients with sarcopeniasix monthsn = 35
SOUTH ARAL SEA MEDICAL JOURNAL
Handgrip strength
upin humans1
1 study
Handgrip strength
upin humans1
Comprehensive therapy increases handgrip strength in humans (patients with sarcopenia).
“These changes were accompanied by significant gains in handgrip strength”
Human trialpatients with sarcopeniasix monthsn = 35
SOUTH ARAL SEA MEDICAL JOURNAL
Irisin
upin humans1
1 study
Irisin
upin humans1
Comprehensive therapy increases irisin in humans (patients with sarcopenia) (1.67-fold).
“irisin increased 1.67-fold”
Human trialpatients with sarcopeniasix monthsn = 35
SOUTH ARAL SEA MEDICAL JOURNAL
Myostatin
downin humans1
1 study
Myostatin
downin humans1
Comprehensive therapy decreases myostatin in humans (patients with sarcopenia) (decreased by 33.6%).
“In patients with sarcopenia, serum myostatin decreased by 33.6%”
Human trialpatients with sarcopeniasix monthsn = 35
SOUTH ARAL SEA MEDICAL JOURNAL
HOMA-IR
downin humans1
1 study
HOMA-IR
downin humans1
Comprehensive therapy decreases HOMA-IR in humans (sarcopenia group (Group 1) compared with T2DM without sarcopenia) (1.74-fold versus 1.41-fold).
“the reduction in insulin resistance was more pronounced in Group 1 (HOMA-IR decreased 1.74-fold versus 1.41-fold in Group 2)”
Human trialsarcopenia group (Group 1) compared with T2DM without sarcopeniasix monthsn = 35
SOUTH ARAL SEA MEDICAL JOURNAL